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BACKGROUND: Germline allele-specific expression (ASE) of the TGFBR1 gene has been reported as a strong risk factor for colorectal
cancer (CRC) with an odds ratio close to 9. Considering the potential implications of the finding, we undertook the task of validating
the initial results in this study.
METHODS: Allele-specific expression was measured using the highly quantitative and robust technique of pyrosequencing. Individuals
from two different populations were studied, one Caucasian-dominated and the other of Ashkenazi Jewish descent, with different
sources of non-tumoral genetic material in each.
RESULTS: Our results showed no statistically significant differences in the degree of ASE between CRC patients and controls,
considering ASE as either a quantitative or a binary trait. Using defined cutoff values to categorise ASE, 1.0% of blood lymphocytes
from informative Israeli cases (total n¼96) were ASE positive (median 1.00; range 0.76–1.31) and 2.2% of informative matched
controls (total n¼90) were ASE positive (median 1.00; range 0.76–1.87). Likewise, normal mucosae from Spanish patients (median
1.03; range: 0.68–1.43; n¼75) did not show significant differences in the degree of ASE when compared with the Israeli patients or
controls.
CONCLUSIONS: Taken together, these results suggest that ASE of TGFBR1 does not confer an increased risk of CRC.
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Colorectal cancer (CRC) is among the four most common cancers
in industrialised countries, and is one of the leading causes of
cancer-related deaths. Although familial clustering of CRC occurs
in 20–30% of all cases, the known highly penetrant autosomal-
dominant and -recessive forms of the disease account for less than
5% of all CRC cases (de la Chapelle, 2004; Lynch et al, 2009).
Although additional low-penetrance alleles have been proposed in
the last few years, the underlying genetic risk factors for CRC
predisposition remain largely unknown (Hemminki et al, 2009).
On the basis of previous evidence that pointed towards the
importance of downstream signalling elements of the transforming
growth factor b (TGF-b) pathway in CRC (Wood et al, 2007), and
the known linkage peak for familial CRC in 9q22–31 where
TGFBR1 is located (Wiesner et al, 2003; Kemp et al, 2006;
Skoglund et al, 2006), we undertook the task of studying the role of
TGFBR1 in CRC predisposition. Although risk-conferring germline
genetic variants in this gene had not been identified, we reported
that germline allele-specific expression (ASE) of TGFBR1,
measured with the SNaPshot technique, occurred in B20% of
informative CRC patients and B3% of informative controls, thus
conferring a substantially increased risk of CRC (odds ratio 8.7,
95% confidence interval (CI): 2.6–29.1) (Valle et al, 2008). This
differential allele-specific expression was suggested to be domi-
nantly inherited and to alter the downstream SMAD-mediated
TGF-b signalling (Valle et al, 2008). A subsequent report showed
that APC
Min/þ;Tgfbr1
þ/  mice developed twice as many intestinal
tumours and colonic carcinomas as APC
Min/þ;Tgfbr1
þ/þ, sup-
porting the role of TGFBR1 gene haploinsufficiency in CRC
development (Zeng et al, 2009). Also, TGFBR1*6A, a common
variant in exon 1 of the gene, has been weakly associated with CRC
(Pasche et al, 2004; Skoglund et al, 2007).
As allele-specific expression of TGFBR1 has the potential to be
used in the clinical evaluation of CRC risk, the aim of this study
was to further investigate the extent of ASE of TGFBR1 in CRC
using the robust and specific pyrosequencing technique for ASE
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sdetermination. In addition, we studied two different populations
with different biological sources of non-tumour genetic material to
evaluate ASE frequency in a variety of populations.
MATERIALS AND METHODS
Patients and controls
Uncultured blood lymphocytes from a total of 426 Ashkenazi
Jewish CRC patients and 433 Ashkenazi Jewish controls were
obtained from a collection of Israeli CRC patients and matched
controls. This series corresponds to a population-based case–
control study (Molecular Epidemiology of Colorectal Cancer;
MECC) of incident CRC, including histopathologically confirmed
cases of all incident CRC diagnosed in northern Israel beginning
31 March 1998 (Poynter et al, 2005). Informed consent was
obtained from all of the subjects who participated in the study. All
426 CRC patients showed tumour microsatellite stability and did
not carry germline mutations in known cancer-predisposing genes.
A total of 178 normal mucosae from Spanish CRC patients
(6% showed tumour microsatellite instability) were obtained
from a hospital-based case–control study (Bellvitge Colorectal
Cancer Study; BCCS). Cases were consecutive patients with a new
diagnosis of colorectal adenocarcinoma attending a University
Hospital in Barcelona. Details about the study population,
interviews and collection of biological samples were published
elsewhere (Landi et al, 2003).
Nucleic acid extraction and cDNA synthesis
Genomic DNA from purified blood lymphocytes and frozen
normal colon mucosa was extracted using standard phenol–
chloroform procedures. For total RNA extraction, the different
tissue sources were processed with TRIzol reagent (Invitrogen,
Carlsbad, CA, USA). In all cases, nucleic acid concentrations and
purities were analyzed with the NanoDrop spectrophotometer, and
the level of degradation of the RNA (RIN number) was checked by
using the RNA Nano assay on the Agilent 2100 Bioanalyzer system
(Agilent Technologies, Santa Clara, CA, USA) when necessary.
Total RNA was treated with DNAse (DNAfree, Ambion, Austin,
TX, USA) before cDNA synthesis (Transcriptor First Strand cDNA
Synthesis Kit, Roche Diagnostics GmbH, Mannheim, Germany).
Genotyping of transcribed SNPs
Current techniques for ASE determination require heterozygous
markers in the transcribed regions of the gene to discriminate
between its two alleles. The transcribed markers we used were four
SNPs located in the 30-UTR region: rs334349, rs420549, rs7850895
and rs1590. Owing to the fact that rs334349 and rs1590 are in
strong linkage disequilibrium, only the latter was genotyped to
determine the informativeness of both. Three commercially
available TaqMan SNP genotyping assays were used to genotype
rs420549 (C_662618_1), rs7850895 (C_29248567_20) and rs1590
(C_2945143_10) (Applied Biosystems Inc., Foster City, CA, USA).
Reactions were performed following the instructions provided by
the manufacturer.
ASE determination by pyrosequencing
PCR and pyrosequencing reactions for rs334349, rs1590 and
rs420549 were performed as described previously (Guda et al,
2009). For rs7850895, PCR and sequencing primers were designed
using the PSQ Assay Design software provided by the manufac-
turer: PCR-fw-50-TCATGCCATATGTAGTTGCTGTAG-30; biotiny-
lated PCR-rv-50-ACACCCCTAAGCATGTGGAGA-30; and SEQ-50-C
CTAGTGCAAGTTACAATAT-30. After PCR, DNA and cDNA
amplification products were sequenced on a PyroMark MD
pyrosequencing instrument (Qiagen, Chatsworth, CA, USA).
The proportions of individual alleles for each SNP were obtained
from the PyroMark MD software calculations. The medians and
standard deviations (s.d.) of the triplicates for both DNA and
cDNA were calculated for each SNP. To obtain an ASE value, the
ratio of the common vs the rare allele in the cDNA was normalised
to the respective ratio in the DNA: cDNA (median common allele/
median rare allele)/DNA (median common allele/median rare
allele). The final ASE value was calculated as the median of the ASE
values obtained for the SNPs studied in each sample.
Before the complete analysis of all informative samples, we
tested the robustness and reproducibility of pyrosequencing
compared with SNaPshot, the technique used in the original
report (Valle et al, 2008), by randomly choosing 10 informative
samples and measuring ASE using both techniques. SNaPshot was
carried out as described previously (Valle et al, 2008) and ASE
value calculations were performed as described above for both
techniques. Pyrosequencing yielded lower variability in ASE
among different SNP markers and it was able to obtain valuable
results in situations when SNaPshot was not able to assess ASE
(Supplementary Table 1). Guda et al (2009) previously reported
additional information showing that ASE results obtained by
pyrosequencing can be reproduced by SNaPshot, supporting the
ability of pyrosequencing to detect allelic imbalances.
Statistical analyses
Pairwise comparisons between cases and controls were performed
using the Wilcoxon’s rank-sum test and Bonferroni correction was
applied to account for the two comparisons performed: MECC
cases vs MECC controls and MECC cases vs BCCS cases.
To dichotomise the ASE variable, cutoff points were established
based on the ASE values obtained in cancer-free controls
(median±(2 s.d.)). When ASE was considered as a binary
variable, comparisons of proportions between cases and controls
were performed using a likelihood ratio test derived from logistic
regression adjusting for population source.
RESULTS
Among a total of 426 Ashkenazi Jewish CRC patients from the
Israeli MECC study, 115 (27%) were informative for at least one
SNP tested: 88 (20.7%) for rs334349 and rs1590, 65 (15.3%) for
rs420549 and 18 (4.2%) for rs7850895. Of a total of 433 Ashkenazi
Jewish MECC controls, 112 (25.9%) were informative: 81 (18.7%)
for rs334349 and rs1590, 59 (13.6%) for rs420549 and 19 (4.4%) for
rs7850895. Of 178 normal mucosae from a Spanish collection of
Caucasian CRC patients (BCCS), 88 (49.4%) were heterozygous for
at least one SNP genotyped: 64 (36%) for rs334349 and rs1590, 64
(36%) for rs420549 and 18 (10%) for rs7850895. Three of the 88
had no RNA available.
ASE values were obtained for 96 (83.5%) informative MECC
CRC patients, 90 (80.4%) informative MECC controls and
75 (85.2%) informative BCCS CRC patients. The ASE values
obtained for cases and controls are shown in Figure 1. For the
MECC series alone, values range from 0.76 to 1.31 (median: 1.00)
in cases, and from 0.76 to 1.87 (median: 1.00) in controls
(Figure 1A). When ASE was considered as a continuous variable,
no differences were detected between cases and controls (median
difference  0.002; 95% CI:  0.027 to 0.032; P¼0.86). Although
observed data suggest that ASE is a quantitative trait, ASE was
transformed into a binary trait (ASE vs non-ASE) to facilitate the
interpretation of the results. For this purpose, cutoff points were
defined based on the results obtained in controls (median
±(2 s.d)¼1.00±(2 0.157)). Under that criterion, 1.0% (1 out
of 96) of informative CRC patients and 2.2% (2 out of 90) of
informative controls showed ASE of TGFBR1 (P¼0.52) (Figure 2).
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patients (median 1.00; range 0.76–1.31) and BCCS patients
(median 1.03; range 0.68–1.43) (median difference 0.026; 95%
CI:  0.001 to 0.059; P¼0.06). Consistent with this analysis, no
differences were identified between MECC and BCCS CRC patients
when ASE was treated as a binary variable (P¼0.20), suggesting
that ethnic origin (Ashkenazi Jewish and Caucasian) and the
source of biological material assessed (uncultured blood lympho-
cytes and normal colon mucosae) do not have a major influence on
TGFBR1 ASE assessment. This allowed us to combine the two
groups of CRC patients and compare them with the available group
of controls (Figures 1B and 2). Combining all data from MECC and
BCCS subjects, no differences were detected between CRC patients
and controls when considering ASE as either a quantitative
(median difference  0.010; 95% CI:  0.037 to 0.017; P¼0.48) or a
binary variable (P¼0.52, adjusted by population).
The RNA quality of subjects with ASE in both the BCCS and
MECC series was checked to confirm that they had been classified
as such owing to the presence of real allelic imbalances and not
owing to technical artefacts caused by poor RNA quality. In all
samples where the source RNA was available, the RIN value was
above 6. To ensure that our results were not affected by poor
performance of the PCR/pyrosequencing reaction owing to low
RNA quality, a more stringent analysis was carried out, including
only those samples whose s.d. among pyrosequencing triplicates
was below 0.20. Similar to the results using the entire sample, no
differences were detected between CRC patients and controls
(Supplementary Figure 1).
DISCUSSION
The presence of allelic imbalances is well known to be widespread
throughout the transcriptome and has been associated with cancer
risk in some instances (Yan et al, 2002; Raval et al, 2007; Chen
et al, 2008). In a previous report, we suggested that ASE of TGFBR1
confers a substantially increased risk of CRC (odds ratio 8.7),
potentially placing ASE of TGFBR1 among the major contributors
to the genetic predisposition to both familial and sporadic CRC
(Valle et al, 2008). The main significance of those findings pertains
to early detection and prevention of CRC, therefore requiring
validation in larger series and different populations for future
implementation in clinical practice. Here, using a more robust
technique for ASE determination, studying Ashkenazi Jewish and
Caucasian populations, and using different sources of non-tumoral
genetic material, we identified no differences in the degree or
frequency of ASE of TGFBR1 between CRC patients and controls,
discarding its role in CRC predisposition. Our results are
supported by the study by Guda et al (2009), in which it was
concluded that ASE of TGFBR1 is unlikely to be the major driver of
linkage in some colon neoplasia families to the 9q22.2–31.2 region,
in which TGFBR1 is located, and that ASE is not associated with
sporadic CRC (n¼44). Recently, Carvajal-Carmona et al (2010)
reported no evidence of genetic variation at TGFBR1 as a
predisposing factor for CRC and found no increased level of
TGFBR1 ASE in 24 familial CRC patients compared with
45 informative controls. In fact, ASE turned out to be more
prevalent among controls than among cases.
Very recently, two additional studies on ASE of TGFBR1 were
published. In the first study, ASE of TGFBR1, assessed by
SNaPshot, was found in approximately 10% of CRC patients
(15% of informative patients), agreeing with our initial report;
however, no controls were included for comparison (Pasche et al,
2010). In the second study, where ASE was measured by
pyrosequencing, 109 informative cases and 125 informative
controls were studied. No differences were identified when ASE
was considered as a binary variable; however, when treated with a
continuous variable, ASE was significantly higher in cases than in
controls. However, the differences identified between CRC patients
and controls were very subtle and definitely not useful for cancer
risk assessment (Tomsic et al, 2010). Table 1 shows the main
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Figure 1 TGFBR1 ASE distributions in cases and controls. (A) TGFBR1 ASE in MECC controls (n¼90), MECC CRC patients (n¼96) and BCCS CRC
patients (n¼75). (B) TGFBR1 ASE in CRC patients (n¼171) and controls (n¼90). The boxes represent the inter-quartile range of distributions (25–75th
percentile); the horizontal lines within the boxes represent the medians; and the vertical lines represent the 5 and 95th percentiles.
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Figure 2 TGFBR1 ASE distribution in 171 CRC patients (96 MECC
(black dots) and 75 BCCS (grey dots) CRC patients) and 90 controls. The
median and cutoff points, defined as the median±2 s.d. of controls, used
to categorise ASE are indicated as discontinuous lines.
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of ASE of TGFBR1 in CRC risk.
Several features differentiate the original and present studies,
and important consequences might have derived from these
differences. The use of different assays for ASE determination and
the exclusion of cases that showed high variability among
replicates (exclusion of samples with low-quality source RNA
shown in Supplementary Material) have likely increased the
robustness of our study. Tomsic et al (2010) also found that the
SNaPshot technology used for ASE determination gave incon-
sistent results, as evidenced by considerably larger standard
deviations compared with pyrosequencing, and that high RNA
quality is essential for reproducibility of ASE.
Some SNP markers and sources of nucleic acids used were also
different. The rs7871490 SNP, located in the 30-UTR of TGFBR1,
was used as a marker in the original study (Valle et al, 2008), but
not in the present one. We previously found that the marker was
very useful because it allowed us to significantly increase the
number of informative individuals from 40 to 55–60%. This SNP is
located in a region of repetitive sequence, 50-GGGGGTTTTTTTT
TTGTTTTTTTTTT[G/T]TTGTTGTTGTTTTTGGGCCATTTCT-30,
which might have affected the correct performance of SNaPshot
owing to the design and molecular basis of the technique. When
excluding all individuals from the original study whose ASE value
was only based on the results obtained from the analysis of
rs7871490 (16 out of 29 CRC patients and 3 out of 3 controls with
ASE values 41.5), the proportion of ASE in informative CRC
patients drops from 21% (29 out of 138) to 13% (13 out of 97) and
in informative controls from 3% (3 out of 105) to 0% (0 out of 76).
Likely because of the repetitive sequences in the flanking region of
rs7871490, we were not able to design a pyrosequencing assay,
which precluded a direct comparison between SNaPshot and
pyrosequencing. A subset of individuals within this group
belonged to the so-called ‘group 2’, which was characterised by a
particular haplotype significantly over-represented among ASE
CRC patients (Valle et al, 2008). To increase the number of
informative individuals, the rs420549 and rs7850895 allelic
markers were included in this study. This resulted in an increase
of 22 out of 75 (29%) informative BCCS CRC patients (three of
which showed ASE), 22 out of 96 (23%) informative MECC CRC
patients (one showed ASE) and 28 out of 90 (31%) informative
MECC controls (two showed ASE). In short, all ASE individuals
were informative for only either rs420549 or rs7850895. This
observation, together with what has been discussed above about
rs7871490, suggests that ASE might be more common among
individuals who carry minor alleles for specific TGFBR1 SNPs, and
Table 1 Summary of the characteristics and results obtained in different studies on ASE of TGFBR1 and CRC risk
ASE: Cases vs controls
a
Study Population
Nucleic acid
source Methodology
Allelic
markers
Informative
cases; controls Quantitative
Binary
(ASE vs non-ASE)
Valle et al (2008) C B90%
O B10%
Peripheral blood SNaPshot rs334348
rs7871490
rs334349
rs1590
138; 105 P¼0.12 Wilcoxon
test
P¼0.02
Permutation test
Cutoff: o0.67, X1.5
(ROC analysis)
ASE: 29/138; 3/105
P¼7.66 10
 5
Guda et al (2009) C B89%
AA B9%
O B2%
Lymphoblastoid
cell line (EBV)
Normal colon
mucosa
Pyrosequencing rs868
rs334348
rs334349
rs420549
rs1590
Familial: 46; 17
Sporadic: 44; 0
N/A Cutoff: o0.67, X1.5
(Valle et al, 2008)
Familial ASE: 2/46; 0/17
Sporadic ASE: 0/44
Carvajal-
Carmona et al
(2010)
C B100% Lymphoblastoid
cell line (EBV)
Genescan
SNaPshot
*6A/9A
rs1590
Familial: 24; 45 P¼0.09 Wilcoxon
test
b
P¼0.13 t-test
b
Cutoff: o0.67, X1.5
(Valle et al, 2008)
ASE: 7/24; 12/45
P¼0.83
Pasche et al
(2010)
C B83%
AA B12%
O B5%
Lymphoblastoid
cell line (EBV)
SNaPshot rs334348
rs7871490
rs334349
rs1590
74; 0 N/A Cutoff: o0.67, X1.5
(Valle et al, 2008)
ASE: 11/74
Tomsic et al
(2010)
C B92%
AA B8%
Peripheral blood Pyrosequencing rs868
rs334348
rs334349
rs420549
rs1590
109; 125
c P¼0.009;0.006
Wilcoxon test
P¼0.081;0.077
Permutation test
P¼0.003;0.007
Permutation
(median)
Cutoff: o0.67, X1.5
(Valle et al, 2008)
ASE: 2/109; 2/125
Cutoff: o0.9, X1.1
(ROC analysis)
ASE: 51/109; 39/125
P¼0.06
This study Ash 100%
C 100%
Uncultured
lymphocytes
(Ash)
Normal colon
mucosa (C)
Pyrosequencing rs334349
rs7850895
rs420549
rs1590
Ash: 96; 90
C: 75; 0
Ash: P¼0.86
Wilcoxon (median)
Ash+C: P¼0.48
Wilcoxon (median)
Cutoff: o0.67, X1.5
(Valle et al, 2008)
Ash ASE: 0/96; 2/90
Ash+C ASE: 0/171; 2/90
Cutoff: o0.68, X1.31
(median±2 s.d.)
Ash ASE: 1/96; 2/90
P¼0.52
Ash+C ASE: 4/171; 2/90
P¼0.52
Abbreviations: AA¼African-American; ASE¼allele-specific expression; Ash¼Ashkenazi Jewish; C¼Caucasian; CRC¼colorectal cancer; EBV¼Epstein–Barr virus; NA¼not
available; O¼Others; ROC¼receiver operating characteristic.
aASE measured as (AcDNA/BcDNA)/(AgDNA/BgDNA), A being the common allele and B the rare allele.
bASE trend
was more pronounced in the controls than in the cases.
cForty-nine cases were the same as in Valle et al (2008).
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SNP markers used to define informative individuals. Nevertheless,
our results point to a similar frequency of ASE among cases and
controls.
The possibility of ASE being tissue specific has been suggested
previously (Cowles et al, 2002; Wilkins et al, 2007). This was
one concern that arose in the paper from Guda et al (2009), in
which the sources of nucleic acids for ASE determination were
EBV-transformed cultured lymphocytes and normal mucosae from
CRC patients, in contrast to the total blood used in our initial
study (Valle et al, 2008). Carvajal-Carmona et al (2010) also
employed lymphoblastoid cell lines. It is still unknown whether
EBV transformation and/or cell culture alter the allelic expression
of genes. Here, we obtained uncultured blood lymphocytes from
the MECC series, which may well correlate with the total blood
used in our previous study (Valle et al, 2008) or by Tomsic et al
(2010), and normal mucosae from BCCS patients, which can be
compared with the sporadic cases reported in the series from Guda
et al (2009). These results suggest that different (uncultured)
biological sources of genetic material for the determination of
TGFBR1 ASE can be used without distinction.
In the original report, a mostly Caucasian population from
Central Ohio was evaluated, whereas Ashkenazi Israeli and
Caucasian Spanish populations were studied here. The fact that
ASE first seemed to be heavily dependent on allele frequencies left
open the possibility of inter-ethnic variation. The degree of SNP
informativity was different between the two populations (20%
MECC vs 36% BCCS for rs334349 and rs1590; 14% MECC vs 36%
BCCS for rs420549; and 4% MECC vs 10% BCCS for rs7850895);
however, no differences were detected in the level of ASE between
the two populations. Unfortunately, we did not have access to all
types of samples (normal mucosae and lymphocytes) from the
same individuals or populations; therefore, there remains a certain
degree of uncertainty about tissue and ethnic variability.
In conclusion, the improved determination of ASE of TGFBR1
achieved by pyrosequencing revealed no differences between CRC
cases and controls, in both Caucasian and Ashkenazi populations.
The sample size in ASE studies is highly relevant owing to their
dependence on marker informativity and to the difficulties associated
with collection of high-quality germline RNA. Finally, the use of
different sources of non-tumour nucleic acids for ASE determination
adds consistency to our results. However, the lack of informativity
for transcribed SNPs in a substantial proportion of individuals
complicates the task to assess the extent of germline ASE of TGFBR1
in CRC. New technological advances that allow the measurement of
allelic imbalances in a more precise and informative manner will be
of substantial importance to provide a definitive answer to the real
extent of ASE at TGFBR1 in CRC patients.
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